PT2217230T - Prevenção e tratamento de infeções secundárias após infeção viral - Google Patents

Prevenção e tratamento de infeções secundárias após infeção viral

Info

Publication number
PT2217230T
PT2217230T PT88470729T PT08847072T PT2217230T PT 2217230 T PT2217230 T PT 2217230T PT 88470729 T PT88470729 T PT 88470729T PT 08847072 T PT08847072 T PT 08847072T PT 2217230 T PT2217230 T PT 2217230T
Authority
PT
Portugal
Prior art keywords
prevention
treatment
viral infection
secondary infections
following viral
Prior art date
Application number
PT88470729T
Other languages
English (en)
Inventor
Sprenger Norbert
Fichot Marie-Claire
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39102986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2217230(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of PT2217230T publication Critical patent/PT2217230T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
PT88470729T 2007-11-08 2008-11-05 Prevenção e tratamento de infeções secundárias após infeção viral PT2217230T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120259A EP2060257A1 (en) 2007-11-08 2007-11-08 Prevention and treatment of secondary infections following viral infection

Publications (1)

Publication Number Publication Date
PT2217230T true PT2217230T (pt) 2018-04-24

Family

ID=39102986

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88470729T PT2217230T (pt) 2007-11-08 2008-11-05 Prevenção e tratamento de infeções secundárias após infeção viral

Country Status (14)

Country Link
US (2) US20100233129A1 (pt)
EP (2) EP2060257A1 (pt)
CN (1) CN101909615A (pt)
BR (1) BRPI0820183A2 (pt)
CA (1) CA2704977A1 (pt)
ES (1) ES2666678T3 (pt)
MX (1) MX2010005136A (pt)
MY (1) MY157860A (pt)
PT (1) PT2217230T (pt)
RU (1) RU2481844C2 (pt)
SG (1) SG185339A1 (pt)
TR (1) TR201807494T4 (pt)
TW (1) TW200936147A (pt)
WO (1) WO2009059996A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169947A (en) * 2008-03-14 2019-06-19 Nestle Sa Preparation of 6-aminocaproic acid from 5-formyl valeri c acid
UA110325C2 (en) * 2009-07-03 2015-12-25 Australian Biomedical Company Pty Ltd Medicinal carbohydrates for treating respiratory conditions
WO2011136647A1 (en) 2010-04-27 2011-11-03 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2658399B2 (en) 2010-12-31 2024-02-28 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides for use in treating and/or preventing enteric rotavirus infection
ES2667393T3 (es) 2010-12-31 2018-05-10 Abbott Laboratories Oligosacáridos de leche humana para modular inflamación
CN108420076A (zh) * 2010-12-31 2018-08-21 雅培制药有限公司 包含人乳低聚糖和长链多不饱和脂肪酸的营养型制剂以及其用途
BR112013016914A2 (pt) * 2010-12-31 2019-09-24 Abbott Lab combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica
ES2708924T3 (es) 2010-12-31 2019-04-12 Abbott Lab Procedimientos de uso de oligosacáridos de la leche humana para mejorar la salud respiratoria de las vías respiratorias
SG191393A1 (en) 2010-12-31 2013-08-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
SG191394A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
WO2012106662A2 (en) * 2011-02-04 2012-08-09 The Regents Of The University Of California New agents to treat/prevent amoebiasis
US20140371173A1 (en) * 2011-02-10 2014-12-18 Nestec S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
WO2012177556A2 (en) 2011-06-20 2012-12-27 H.J. Heinz Company Probiotic compositions and methods
ES2657744T3 (es) 2011-07-22 2018-03-06 Abbott Laboratories Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal
EP2750523A1 (en) 2011-08-29 2014-07-09 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP2768311B1 (en) * 2011-10-18 2018-02-21 Nestec S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
EP2606897A1 (en) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
CA2894897C (en) * 2012-12-20 2018-09-18 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
WO2016035043A1 (en) * 2014-09-04 2016-03-10 SMITH, Jerome Shelsley Probiotic composition
EP3264920B1 (en) 2015-03-05 2020-12-16 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function
DK3277287T3 (da) 2015-03-31 2024-01-08 Glycom As Blandinger af humane mælke-oligosaccharider, der omfatter 3 '-o-sialyllactose
ES2760351T3 (es) * 2015-08-04 2020-05-13 Suedzucker Ag Utilización profiláctica de inulina contra la sinusitis
CN108289492A (zh) 2015-12-15 2018-07-17 雀巢产品技术援助有限公司 Hmo的混合物
SG11201806868TA (en) * 2016-02-25 2018-09-27 Applied Biological Laboratories Inc Compositions and methods for protecting against airborne pathogens and irritants
EP3498282A1 (en) * 2017-12-12 2019-06-19 Rheinische Friedrich-Wilhelms-Universität Bonn 6'-sialyllactose for use in the treatment of hearing loss

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016449A1 (en) * 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
CA2248971A1 (en) * 1997-10-31 1999-04-30 Kyowa Hakko Kogyo Co., Ltd. .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
SE9904581D0 (sv) 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20001477A (fi) * 2000-06-21 2001-12-22 Carbion Oy Influenssavirusta sitova aine ja sen käyttö
FI20010118A (fi) 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
FI114895B (fi) * 2001-05-14 2005-01-31 Suomen Rehu Oy Ravinnon lisäaine
ATE429233T1 (de) * 2001-06-29 2009-05-15 Glykos Finland Oy Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
PL375071A1 (en) * 2002-10-11 2005-11-14 Wyeth Nutritional formulations containing synbiotic substances
US7893041B2 (en) * 2003-12-05 2011-02-22 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
ES1056525Y (es) 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
BRPI0707620A2 (pt) * 2006-02-10 2011-05-10 Nestec Sa mistura de oligossacarÍdeo
CN101432007A (zh) * 2006-03-07 2009-05-13 雀巢产品技术援助有限公司 合益素混合物

Also Published As

Publication number Publication date
TW200936147A (en) 2009-09-01
EP2060257A1 (en) 2009-05-20
RU2010123174A (ru) 2011-12-20
WO2009059996A1 (en) 2009-05-14
BRPI0820183A2 (pt) 2015-06-23
EP2217230A1 (en) 2010-08-18
US20130131014A1 (en) 2013-05-23
SG185339A1 (en) 2012-11-29
MY157860A (en) 2016-07-29
ES2666678T3 (es) 2018-05-07
AU2008324205A1 (en) 2009-05-14
TR201807494T4 (tr) 2018-06-21
EP2217230B1 (en) 2018-02-28
CA2704977A1 (en) 2009-05-14
CN101909615A (zh) 2010-12-08
RU2481844C2 (ru) 2013-05-20
MX2010005136A (es) 2010-06-02
US20100233129A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
PT2217230T (pt) Prevenção e tratamento de infeções secundárias após infeção viral
PT1951272T (pt) Uso de lactobacillus para o tratamento de infeções virais
ZA201109187B (en) Treatment and prevention of dengue virus infections
IL207575A0 (en) Vaccine for prevention and treatment of hiv infection
HK1146084A1 (en) Methods and compositions for prevention or treatment of rsv infection
HK1156038A1 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
EP2203168A4 (en) METHODS OF TREATING INFECTION WITH FLAVIVIRIDAE FAMILY VIRUSES AND COMPOSITIONS FOR TREATING INFECTION WITH FLAVIVIRIDAE FAMILY VIRUSES
HK1144794A1 (en) Devices for treatment of viral infections
IL195272A0 (en) Methods and compositions for the treatment of viral infections
ZA201303610B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
ZA200802934B (en) Use of lactobacillus for treatment of virus infections
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2521554A4 (en) SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
EP2224943A4 (en) USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS
ZA201100616B (en) Treatment of antibiotic-resistant bacteria infection
EP2217573A4 (en) TREATMENT AND PREVENTION OF VIRUS INFECTIONS
PL2132215T3 (pl) Związki do zapobiegania lub leczenia zakażeń wirusowych i sposoby ich stosowania
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
GB2441094B (en) Methods for treatment and prevention of infection
IL205035A0 (en) Methods of inhibiting viral infection
IL204940A0 (en) Methods of inhibiting viral infection
HK1174256A1 (en) Treatment and prevention of hiv infection hiv
GB0608792D0 (en) Method for treatment and prophylaxis of viral influenza infections
GB0813716D0 (en) Treatment of viral infection
GB201010682D0 (en) Methods for treatment and prevention of infection